Cargando…
The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review
Recurrence of FSGS occurs in 30–40% of allografts. Therapies for recurrence are not well established. We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with trea...
Autores principales: | Araya, Carlos E., Dharnidharka, Vikas R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235904/ https://www.ncbi.nlm.nih.gov/pubmed/22174985 http://dx.doi.org/10.1155/2011/374213 |
Ejemplares similares
-
Rituximab treatment of adults with primary focal segmental glomerulosclerosis
por: Wang, Liuwei, et al.
Publicado: (2023) -
Treatment of Recurrent Focal Segmental Glomerulosclerosis
in Pediatric Kidney Transplant Recipients: Effect of Rituximab
por: Sethna, Christine, et al.
Publicado: (2011) -
Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation
por: Deegens, Jeroen K. J., et al.
Publicado: (2008) -
The Role of Rituximab in Focal Segmental Glomerulosclerosis–Update From Italy
por: Gauckler, Philipp, et al.
Publicado: (2022) -
Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients
por: Park, Hoon Suk, et al.
Publicado: (2014)